European CHMP recommends license extension of nivolumab (Opdivo) and ipilimumab (Yervoy) for colorectal cancer

The proposed license extension for the combination of nivolumab and ipilimumab is for treatment of adults with mismatch repair deficient or microsatellite instability high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy.

Source:

European Medicines Agency